Multiple Keratoacanthomas Arising in the Setting of Sorafenib Therapy: Novel Chemoprophylaxis with Bexarotene

Kong H.H. , Cowen E.W. , Azad N.S. . Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol. 2006; 56(1): 171–172.

Roberts L.R. . Sorafenib in liver cancer: just the beginning. N Engl J Med. 2008; 359(4): 420–422.

Autier J. , Escudier B. , Wechsler J. . Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008; 144(7): 886–892.

Dubauskas Z. , Kunishige J. , Prieto V.G. . Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib: a single institution experience. J Clin Oncol. 2008 ASCO Annu Meet Proc (Post-Meet Ed). 2008; 26 (15 Suppl). Abstract 16101.

Kossard S. , Tan K. , Choy C. . Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J Dermatopathol. 2008; 30(2): 127–134.

Feldman R.J. , Maize J.C. . Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. Int J Dermatol. 2007; 46(1): 77–79.

Rosenblum G.A. . Multiple palmar keratoacanthomas treated with acitretin. J Drugs Dermatol. 2006; 5(10): 1006–1009.

Assaf C. , Bagot M. , Drummer R. . Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol. 2006; 155(2): 261–266.

Talpur R. , Ward S. , Apisarnthanarax N. . Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002; 47(5): 672–684.

Gniadecki R. , Assaf C. , Bagot M. . The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007; 157(3): 433–440. Epub 2007 Jun 6.